Cipher Pharmaceuticals (CPH.TO) Osake Kurssi

Cipher Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

Cipher Pharmaceuticals Inc faces competition from several key players in the market. Some of the main competitors include [competitor 1], [competitor 2], and [competitor 3]. These companies operate in the same industry as Cipher Pharmaceuticals Inc and offer similar products and services. While Cipher Pharmaceuticals Inc has established a strong presence in the market with their innovative solutions, they must continuously strive to stay ahead of the competition and adapt to changing market dynamics.

Cipher Pharmaceuticals Inc. is a renowned Canadian pharmaceutical company with a rich history and established background. Founded in 2000, Cipher focuses on the development and commercialization of innovative prescription products. With a diverse portfolio ranging from dermatology to cardiometabolic disorders, Cipher has gained a strong foothold in the global pharmaceutical market. The company's strategic partnerships and collaborations have propelled its growth and allowed it to bring new treatments to market. Known for its commitment to excellence, Cipher Pharmaceuticals Inc. continues to make significant contributions to the healthcare industry, delivering high-quality products and improving patients' lives worldwide.

Cipher Pharmaceuticals Inc has achieved several significant milestones throughout its history. One notable milestone was the acquisition of Innocutis Holdings LLC in 2014, expanding its product portfolio and market reach. In addition, Cipher successfully secured partnerships and licensing agreements for its pharmaceutical products, strengthening its global presence. The company's focused approach and commitment to research and development have also led to the successful launch of innovative products in various therapeutic areas. Furthermore, Cipher Pharmaceuticals Inc has consistently demonstrated strong financial performance, achieving steady revenue growth and profitability over the years. These achievements highlight the company's dedication towards delivering high-quality pharmaceutical solutions to improve patient outcomes.

Cipher Pharmaceuticals Inc is primarily present in several countries and regions around the world. Some of the key markets where the company operates include Canada and the United States. The company has a significant presence and a strong focus on the North American pharmaceutical market. With its headquarters in Mississauga, Ontario, Cipher Pharmaceuticals Inc also has a presence in various countries globally, including Europe, Latin America, and other international markets. The company's global reach allows it to cater to a diverse range of patients and healthcare professionals, ensuring widespread access to its innovative pharmaceutical products.

Cipher Pharmaceuticals Inc is a company that firmly believes in values such as integrity, innovation, and excellence. With a strong corporate philosophy, Cipher strives to provide healthcare solutions that cater to the diverse needs of patients worldwide. By consistently adopting cutting-edge technologies and research, Cipher is committed to delivering high-quality products that improve patients' quality of life. With a customer-centric approach, the company focuses on building strong relationships with healthcare professionals and stakeholders to ensure the best outcomes. Cipher Pharmaceuticals Inc's dedication to ethical practices and continuous improvement makes it a trusted player in the pharmaceutical industry.

Analyytikot asettavat tällä hetkellä Cipher Pharmaceuticals-osakkeelle keskimääräisen tavoitehinnan 13,98 USD (mediaani: 13,83 USD), mikä merkitsee +47,0 % viimeisimpään hintaan verrattuna. Konsensus perustuu 7 analyytikkoarvioon.

Cipher Pharmaceuticals Analyytikkojen kursstavoitteet 2026

7 analyytikkoa arvioi tällä hetkellä Cipher Pharmaceuticals-osaketta: 6 suosittaa ostoa, 1 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Cipher Pharmaceuticals-yhtiöltä 46,84 M USD liikevaihtoa ja 0,72 USD osakekohtaista tulosta.

Cipher Pharmaceuticals Analyytikkojen kursstavoitteet 2026

Nykyisellä valuuttakurssilla Cipher Pharmaceuticals-osake noteerataan hintaan 8,36 EUR (9,36 USD).

Cipher Pharmaceuticals-osake (CPH.TO) on listattuna 4 pörssissä, muun muassa: Toronto (CPH.TO), Frankfurt (PHE.F), München (PHE.MU).

Cipher Pharmaceuticals Inc is a Canadian company specializing in the development, manufacturing, and marketing of pharmaceutical preparations. The company places great emphasis on research and development to create innovative solutions for patients worldwide. Cipher invests in a variety of therapeutic areas, including dermatology, pain medications, urinary tract diseases, and cardiology. There are products developed for acne, eczema, psoriasis, nail fungus, herpes, and more. Cipher Pharmaceuticals has three main business areas in which it operates: 1. Proprietary Products This business segment focuses on the development and marketing of patented drugs for patients worldwide. The company is strong in dermatology and offers innovative products for skin diseases such as acne, eczema, and psoriasis. An example of a patented product from Cipher is the medical gel Absorica for acne. The patented technology ensures controlled release of isotretinoin, an active ingredient known for its effectiveness in severe acne. 2. In-Licensing and Acquisitions Cipher Pharmaceuticals is also active in the in-licensing and acquisition market. The company acquires the rights to drugs from other companies that are either on the market or still in the development phase. Through this business segment, Cipher gains access to new technologies and drug products that can complement the company's product portfolio. Cipher also seeks partnerships and joint ventures to further grow and expand. 3. Licensing Cipher Pharmaceuticals also offers licenses for its technologies and products on the global market. Cipher has partnerships in European countries, Canada, and the United States. Cipher continuously invests in research and development to create innovative drugs for patients. The company aims to reformulate active ingredients such as isotretinoin to improve their effectiveness while reducing side effects. Overall, Cipher Pharmaceuticals is an innovative, research-based company. The development of patented medications as well as in-licensing and acquisitions enable the company to expand its product portfolio and fulfill its vision of supporting patients.

odotettu liikevaihto Cipher Pharmaceuticals on 46,84 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Cipher Pharmaceuticals on 18,88 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Cipher Pharmaceuticals:n hinta-voitto-suhde (P/E) on tällä hetkellä 12,93. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Cipher Pharmaceuticals-osakkeen arvostusta.

Cipher Pharmaceuticals:n hinta-myynti-suhde (P/S) on tällä hetkellä 5,21. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Cipher Pharmaceuticals-osakkeen arvostuskennuslukuna.

Cipher Pharmaceuticals:n Eulpool-laatuscore on 5/10.

Cipher Pharmaceuticals:n ISIN on CA17253X1050. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Cipher Pharmaceuticals:n WKN on A0B85L. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Cipher Pharmaceuticals:n ticker on CPH.TO. Tämä pörssinoteeraus käytetään Cipher Pharmaceuticals-osakkeiden kauppaan pörssissä.